MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) indication : diabetes mellitus, type 2

The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health November 2017, 2017
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Canada Peptides / Therapeutic Use Cost-benefit Analysis Hypoglycemic Agents / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Hypoglycemic Agents / Economics
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534071
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus
Item Description:	"Final."
Physical Description:	1 PDF file (9 pages)